CRISPR Therapeutics reported a net loss of $126.4 million for Q2 2024, compared to a net loss of $77.7 million in Q2 2023. The company recorded no collaboration revenue in Q2 2024, contrasting with $70 million in the same period last year. Research and development expenses decreased to $80.2 million from $101.6 million year-over-year, primarily due to reduced external research costs.The company's collaboration expense with Vertex increased to $52.1 million from $44.6 million in Q2 2023, mainly driven by commercial and manufacturing costs related to the CASGEVY program. General and administrative expenses remained relatively stable at $19.5 million. Other income increased to $26.1 million from $18.4 million, primarily due to higher interest income from investments.As of June 30, 2024, CRISPR Therapeutics maintained a strong financial position with $2.01 billion in cash, cash equivalents and marketable securities. The company completed a registered direct offering in February 2024, raising net proceeds of $279.0 million. Management believes current funding will support operating expenses and capital expenditures for at least the next 24 months as they continue advancing their therapeutic programs across hemoglobinopathies, immuno-oncology, and other areas.

CRISPR Therapeutics reported a net loss of $126.4 million for Q2 2024, compared to a net loss of $77.7 million in Q2 2023. The company recorded no collaboration revenue in Q2 2024, contrasting with $70 million in the same period last year. Research and development expenses decreased to $80.2 million from $101.6 million year-over-year, primarily due to reduced external research costs.The company's collaboration expense with Vertex increased to $52.1 million from $44.6 million in Q2 2023, mainly driven by commercial and manufacturing costs related to the CASGEVY program. General and administrative expenses remained relatively stable at $19.5 million. Other income increased to $26.1 million from $18.4 million, primarily due to higher interest income from investments.As of June 30, 2024, CRISPR Therapeutics maintained a strong financial position with $2.01 billion in cash, cash equivalents and marketable securities. The company completed a registered direct offering in February 2024, raising net proceeds of $279.0 million. Management believes current funding will support operating expenses and capital expenditures for at least the next 24 months as they continue advancing their therapeutic programs across hemoglobinopathies, immuno-oncology, and other areas.